Companies/Umecrine Cognition AB
Follow

Umecrine Cognition AB

Nasdaq First North GM (Sweden)

Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (neurosteroids). The company's primary focus is on the development and commercialization of novel therapeutics to treat CNS related disorders in patients with liver disease, such as Hepatic Encephalopathy (HE) in patients with liver cirrhosis.

Sector:
HEALTH CARE
 
Top
News
No available news yet for Umecrine Cognition AB
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
Nasdaq First North GM
Sweden (SE)
Details of share in Umecrine Cognition AB with ticker
Status
Inactive
Amount of instruments
—
Currency
SEK
Type
Price
Pre-money
Time
Files
Listing
2021 Q4
Direct listing of Umecrine Cognition AB on Nasdaq First North GM

We have reserved some of the more detailed information for our registered users. Please sign in if You have already registered.

Get access to Events, Instruments, Documents, Media and much more by signing up for FREE!

Partially obscured image showing event data
Sign up for FREE
People
Magnus Doverskog
CEO
Viktor Drvota
Chairman of the board
Thomas Paul Blackburn
Board member
Bruce Frederic Scharschmidt
Board member
John Öhd
Board member
Carl Torbjörn Bäckström
Board member
Viktor Drvota
Board member
Company Details
Sector
HEALTH CARE
Website
Address
Fogdevreten 2
Zip code
171 65
City/district
Solna
Country
Sweden (SE)
Phones
Email
[email protected]
Registration number
556698-3655
LEI code
894500AF89I6QWOX2Q84
First trade date
Registration date
14 Feb 2006
Short name
Umec

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More